How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Posterior Segment Eye Disorder Treatment Market
- By Disorder Type: Age-related Macular Degeneration (AMD), Diabetic Retinopathy, Retinal Vein Occlusion, Macular Edema, Posterior Uveitis
- By Treatment Modality: Anti-VEGF Therapy, Corticosteroid Therapy, Laser Photocoagulation, Vitrectomy Surgery, Photodynamic Therapy
- By Drug Class: Monoclonal Antibodies, Corticosteroids, Tyrosine Kinase Inhibitors, Immunosuppressants
- By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Specialty Eye Care Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Age-related Macular Degeneration (AMD) leads By Disorder Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Posterior Segment Eye Disorder Treatment Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Disorder Type 5
Treatment Modality 5
Drug Class 4
End User 4
Companies profiled
Regeneron Pharmaceuticals Inc.
Novartis AG
Roche Holding AG
Bayer AG
Alcon (Novartis subsidiary)
Santen Pharmaceutical Co. Ltd.
Allergan (AbbVie)
Genentech (Roche subsidiary)
Ophthotech Corporation
Chengdu Kanghong Pharmaceutical Group Co. Ltd.
HUB Pharmaceuticals
MediBeacon Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Regeneron Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Alcon (Novartis subsidiary)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Santen Pharmaceutical Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Allergan (AbbVie)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Genentech (Roche subsidiary)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Ophthotech Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Chengdu Kanghong Pharmaceutical Group Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →HUB Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →MediBeacon Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Molecular Partners AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Oxurion NV
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Kodiak Sciences
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,099M by 2033 · 4.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Age-related Macular Degeneration (AMD)52.0
- Diabetic Retinopathy8.7
- Retinal Vein Occlusion12.2
- Macular Edema11.8
- Posterior Uveitis15.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,474M → $2,005M · 3.9%
Europe$1,027M → $1,442M · 4.3%
Asia Pacific$938.1M → $1,419M · 5.3%
Latin America$580.7M → $762.7M · 3.5%
Middle East and Africa$446.7M → $607.7M · 3.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.922026
3.942027
3.942028
3.962029
3.982030
3.992031
3.992032
4.012033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Regeneron Pharmaceuticals Inc.15.1
- Novartis AG18.4
- Roche Holding AG9.5
- Bayer AG12.9
- Alcon (Novartis subsidiary)7.2
- Santen Pharmaceutical Co. Ltd.8.8
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Disorder Type23.7%
Treatment Modality28.0%
Drug Class32.6%
End User15.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.1
- Europe23.1
- Asia Pacific22.8
- Latin America12.2
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 84 | 80 | 82 | 87 | 99 | 94 | 88 |
| Novartis AG | 74 | 70 | 76 | 75 | 88 | 75 | 76 |
| Roche Holding AG | 64 | 76 | 73 | 71 | 78 | 75 | 73 |
| Bayer AG | 65 | 77 | 76 | 68 | 69 | 74 | 72 |
| Alcon (Novartis subsidiary) | 67 | 70 | 67 | 75 | 70 | 57 | 68 |
| Santen Pharmaceutical Co. Ltd. | 46 | 48 | 68 | 47 | 64 | 60 | 56 |
| Allergan (AbbVie) | 48 | 44 | 60 | 46 | 44 | 41 | 47 |
| Genentech (Roche subsidiary) | 39 | 54 | 43 | 45 | 52 | 41 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Regeneron Pharmaceuticals Inc.
- Novartis AG
- Roche Holding AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Novartis AG | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Roche Holding AG | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Bayer AG | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Alcon (Novartis subsidiary) | ✓ | − | ◐ | ◐ | ◐ | − |
| Santen Pharmaceutical Co. Ltd. | ◐ | ◐ | ◐ | − | − | − |
| Allergan (AbbVie) | − | − | ◐ | − | − | − |
| Genentech (Roche subsidiary) | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Regeneron Pharmaceuticals Inc.88
2Novartis AG76
3Roche Holding AG73
4Bayer AG72
5Alcon (Novartis subsidiary)68
6Santen Pharmaceutical Co. Ltd.56
7Allergan (AbbVie)47
8Genentech (Roche subsidiary)46
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Regeneron Pharmaceuticals Inc.
Challenger4
Strong scale, closing on the leaders.
Novartis AGRoche Holding AGBayer AGAlcon (Novartis subsidiary)
Niche3
Specialists in a single segment or region.
Santen Pharmaceutical Co. Ltd.Allergan (AbbVie)Genentech (Roche subsidiary)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disorder Type in North America, then scale across Posterior Segment Eye Disorder Treatment Market — a $167M beachhead inside a $2.37B market.
Beachhead (SOM)$167Mobtainable near-term
Serviceable (SAM)$959Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Age-related Macular Degeneration (AMD)
Best fit — highest urgency & budget in Disorder Type.
Economic buyer77 fit
Diabetic Retinopathy
Strong fit — clear ROI and a fast path to value.
End user67 fit
Retinal Vein Occlusion
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disorder Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Drug Class
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel26%
Digital / self-serve23%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Disorder Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Posterior Segment Eye Disorder Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified25%
Evaluation14%
Closed-won7%
$16.3KCAC
$74KLTV
4.5:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Posterior Segment Eye Disorder Treatment Market is a resilient opportunity — $2.08B by 2033, compounding at 5.4%.
TAM · 2025$1.37Btoday
TAM · 2033$2.08Bforecast
CAGR5.4%2027–2033
Cumulative$15.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.08BTotal addressable market
SAM$747MServiceable available market
SOM$158MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.4% CAGR
Demand compounds through 2033, outpacing GDP across Disorder Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disorder Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.08BLarge & growingTAM by 2033 at 5.4% CAGR
$747MServiceable nowreachable with today’s model
$158MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.62BBear3.5% CAGR
$2.08BBase5.4% CAGR
$2.67BBull7.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Posterior Segment Eye Disorder Treatment Market — a $2.89B market by 2033. Plan: grow share from 7.5% to 15.1%.
Market size · 2033$2.89Btotal addressable
Market CAGR11.4%2027–2033
Target share15.1%from 7.5% today
Revenue ambition$436Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.5% | 15.1% | On track |
| Revenue | $232M | $436M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 31.2% | 41.7% | Ahead |
| Customer retention | 86.4% | 96.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disorder Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disorder Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $48M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Disorder Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Posterior Segment Eye Disorder Treatment Market conversation — a $4.14B market you can size, segment and defend in minutes.
Market size · 2033$4.14Btotal opportunity
Growth4.4%CAGR to 2033
Addressable buyers1,660+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disorder Type
Goal Grow share in Disorder Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 3 mopayback period
$69K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Regeneron Pharmaceuticals Inc.Novartis AGRoche Holding AGBayer AGAlcon (Novartis subsidiary)Santen Pharmaceutical Co. Ltd.Allergan (AbbVie)Genentech (Roche subsidiary)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Posterior Segment Eye Disorder Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Posterior Segment Eye Disorder Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Posterior Segment Eye Disease Treatment Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportPosterior Pituitary Injection Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportPosterior Occipital Cervical Thoracic Fixation System Market
Market size, share, segmentation and regional forecast.
$752M market · 2025 base year
View reportPosterior Chamber-Phakic Refractive Lens Market
Market size, share, segmentation and regional forecast.
$753M market · 2025 base year
View reportPosterior Chamber Intraocular Lens Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportPosterior Chamber Acrylic Aspheric Intraocular Lens Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportPosterior Cervical Spine System Market
Market size, share, segmentation and regional forecast.
$501M market · 2025 base year
View reportPosterior Cervical Screw System Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportPosterior Cervical Screw Fixation System Market
Market size, share, segmentation and regional forecast.
$809M market · 2025 base year
View reportPosterior Cervical Fixation System Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportPosterior Cervical Fixation Reconstruction Spine System Market
Market size, share, segmentation and regional forecast.
$381M market · 2025 base year
View reportPostbiotic Supplement Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.